Marker Therapeutics, Inc. Common Stock
$1.18
$0.00 (+0.00%)
$1.17Day Range$1.23
Key Statistics
Market Cap
$19.67M
Shares Outstanding
16.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 7, 1998
Round Lot
100
Locale
US
Trading Data
Day Open
$1.19
Day High
$1.23
Day Low
$1.17
Volume
47.3K
VWAP
$1.20
Prev Close
$1.18
Transactions
--
Acc. Volume
--
About Marker Therapeutics, Inc. Common Stock
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
PHARMACEUTICAL PREPARATIONSSIC 28345 employees2450 HOLCOMBE BLVD, HOUSTON, TX, 77021(713) 400-6400IPO Jan 7, 1998US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001094038
- Composite FIGI
- BBG000GMZP09
- Share Class FIGI
- BBG001SKLLN7
- Ticker Root
- MRKR
- SIC Code
- 2834
About Marker Therapeutics, Inc. Common Stock (MRKR) Stock
Marker Therapeutics, Inc. Common Stock (MRKR) closed the 2026-09-18 session at $1.18, up 0.00% versus the previous close (+0.00). The stock opened at $1.19 and traded between $1.17 and $1.23 during that session. Session trading volume was 47K shares. The volume-weighted average price (VWAP) is $1.20.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Marker Therapeutics, Inc. Common Stock has a market capitalization of $19.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MRKR is listed on the XNAS exchange. The company employs approximately 5 people. Marker Therapeutics, Inc. Common Stock is headquartered in HOUSTON, TX. The recorded listing date is 1998-01-07.
On this page you can find market MRKR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.